{
"schema":"http://google-preview.miscsubjects.com/schemas/jarticle.json",
"status":"published",
"slug":"semaglutide-glp1-agonists",
"title":"semaglutide glp1 agonists",
"kind":"standard",
"summary":"Evidence is being populated by Grok web",
"created":"2026-06-29T17:47:38.507Z",
"body": [
"## Overview\nEvidence is being populated by Grok web search."
],
"facts": {
"converted_from":"markdown",
"original_updated":"2026-06-29T17:47:40.716Z",
"register":"standard",
"category":null
},
"sources": [
{
"id":"s1",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/40829097/",
"title":"Trends in glucagon-like peptide 1 receptor agonist prescribing patterns",
"quote":"From 2018 to 2023, GLP-1 RA prescribing increased significantly, with semaglutide approved for weight loss rising to 60% share in the nondiabetic obese/overweight group.",
"summary":"Analysis of GLP-1 RA prescribing from 2018-2023 shows sharp rise, especially semaglutide for weight loss reaching 60% share in non-diabetic obese/overweight patients.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:47:38.639Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"genesis",
"hash":"7acee6853c646b10997a58ea4f1cf8c08dd2b8ca96a81a53675c65455eeb1b48",
"quote_sha256":"0fd029c6a70cfe030ffc41450877010c944fc51a77fc7a27b2687440a9d81cba"
},
{
"id":"s2",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/41824845/",
"title":"GLP-1 receptor agonists for weight loss: A systematic review and meta-analysis of randomized controlled trials",
"quote":"GLP-1 receptor agonists significantly increase the likelihood of weight loss versus placebo, with tirzepatide and semaglutide demonstrating the greatest relative efficacy among agents evaluated.",
"summary":"2026 meta-analysis of 16 RCTs confirms GLP-1 RAs (esp. tirzepatide and semaglutide) superior for weight loss vs placebo.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:47:38.639Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"7acee6853c646b10997a58ea4f1cf8c08dd2b8ca96a81a53675c65455eeb1b48",
"hash":"7a8ee73d77006c520a32629570c193ca96a8dab23fb227ac490c44530b8f1df2",
"quote_sha256":"e1ded765184f66c5bdb43cea297f5d0a618f6535061e32d116bdf244c5057519"
},
{
"id":"s3",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/40536520/",
"title":"Semaglutide versus other GLP-1 receptor agonists in patients with MASLD",
"quote":"Compared to other GLP-1RAs, semaglutide was associated with a 14% lower risk of primary composite outcomes... reduced risks of all-cause mortality (aHR, 0.68) and major adverse liver outcomes (aHR, 0.79).",
"summary":"2025 study finds semaglutide superior to other GLP-1RAs in MASLD patients for reducing mortality and liver outcomes.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:47:38.639Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"7a8ee73d77006c520a32629570c193ca96a8dab23fb227ac490c44530b8f1df2",
"hash":"f65b4ec7f9390db2b9e58da32b4113d170a51fe4615cf7d6a8eb0ae4b77314f0",
"quote_sha256":"e13ccc054838bd330984ab82b886a61358e39156836729a4ada18fb1084c710e"
},
{
"id":"s4",
"type":"clinical_trial",
"url":"https://clinicaltrials.gov/study/NCT05564117",
"title":"Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range (OASIS 4)",
"quote":"Participants will either get semaglutide 25 milligram (mg) once daily or placebo once daily. This study will last for 72 weeks...",
"summary":"Ongoing/completed OASIS 4 trial evaluating daily oral semaglutide 25mg for weight management in overweight/obese adults.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:47:38.639Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"f65b4ec7f9390db2b9e58da32b4113d170a51fe4615cf7d6a8eb0ae4b77314f0",
"hash":"be117bf019ae2c28fe14883ac9dafa1865dda91540914d6c4648a178a827cec7",
"quote_sha256":"df3ae37c0a3252105ef1ad5b21fcd303e126e93daaa9ca4138b4877bd073e126"
},
{
"id":"s5",
"type":"review",
"url":"https://www.nature.com/articles/s41591-025-03978-z",
"title":"A systematic review and meta-analysis of the efficacy and safety of GLP-1 receptor agonists",
"quote":"Semaglutide was effective in reducing major adverse cardiovascular events and reducing pain in knee osteoarthritis. Tirzepatide was effective in...",
"summary":"2025 Nature Medicine review/meta-analysis on efficacy/safety of GLP-1 RAs including semaglutide benefits for CV events and osteoarthritis.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:47:38.639Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"be117bf019ae2c28fe14883ac9dafa1865dda91540914d6c4648a178a827cec7",
"hash":"91a9f0135ddc0ef1e9149006e23aac6f13404b894edd5302dcdcb41a4ef5fa00",
"quote_sha256":"da4300d821b85c11d0a71ac5344f7b8c52aa90819b854552773fb34cb5f5f379"
}
],
"type":"article",
"updated":"2026-10-08T11:49:29.748Z",
"version":1,
"hash":"4b97a2982dcbb6cd96f2dcc983306c7e074e2b01969550b0b48e6f86d0d0a299",
"styling": {
"scope":"shared",
"how":"no value on the page is set by hand: each comes from this theme, and each theme value becomes the CSS variable named beside it. PATCH http://google-preview.miscsubjects.com/api/jarticles/theme changes them.",
"widget_style": {
"what":"every widget may carry style: {…}; these are the only keys it reads",
"rotate":"degrees, a number",
"offset_x":"pixels, a number",
"offset_y":"pixels, a number",
"pulse":"true to pulse"
},
"theme": {
"color": {
"page_bg":"#f5f5f7",
"sheet_bg":"#ffffff",
"ink":"#1d1d1f",
"soft":"#424245",
"muted":"#6e6e73",
"dim":"#86868b",
"line":"#d2d2d7",
"accent":"#0071e3",
"accent_soft":"rgba(0,113,227,0.08)",
"link":"#0066cc",
"selection":"rgba(0,113,227,0.18)",
"widget_bg":"#f5f5f7",
"widget_border":"#d2d2d7",
"card_bg":"#ffffff",
"code_bg":"#f5f5f7",
"json_bg":"#161b19",
"json_ink":"#e6e1d4",
"json_key":"#7fd3c3",
"json_string":"#e9c46a",
"json_number":"#f4a261",
"json_bool":"#c792ea",
"json_null":"#928d7e",
"json_punct":"#6b6759",
"json_bar":"#0e1512",
"kind_badge_bg":"#0e6e60",
"kind_badge_ink":"#ffffff"
},
"color_dark": {
"page_bg":"#000000",
"sheet_bg":"#1d1d1f",
"ink":"#f5f5f7",
"soft":"#d2d2d7",
"muted":"#a1a1a6",
"dim":"#86868b",
"line":"#424245",
"accent":"#2997ff",
"accent_soft":"rgba(41,151,255,0.12)",
"link":"#2997ff",
"selection":"rgba(41,151,255,0.25)",
"widget_bg":"#2c2c2e",
"widget_border":"#424245",
"card_bg":"#1d1d1f",
"code_bg":"#2c2c2e",
"json_bg":"#0a0d0c",
"json_ink":"#e6e1d4",
"json_key":"#7fd3c3",
"json_string":"#e9c46a",
"json_number":"#f4a261",
"json_bool":"#c792ea",
"json_null":"#757062",
"json_punct":"#5d665f",
"json_bar":"#060807",
"kind_badge_bg":"#4fc1ab",
"kind_badge_ink":"#0b0f0d"
},
"font": {
"display":"-apple-system,BlinkMacSystemFont,\"SF Pro Display\",\"SF Pro Text\",\"Helvetica Neue\",Helvetica,Arial,sans-serif",
"body":"-apple-system,BlinkMacSystemFont,\"SF Pro Display\",\"SF Pro Text\",\"Helvetica Neue\",Helvetica,Arial,sans-serif",
"mono":"ui-monospace,SFMono-Regular,\"SF Mono\",Menlo,Consolas,monospace",
"google_fonts":""
},
"size": {
"body":"17px",
"small":"17px",
"eye":"17px",
"lead":"17px",
"h1":"52px",
"h2":"34px",
"h3":"22px",
"byline":"17px",
"h1_measure":"none",
"code":"17px",
"json":"17px",
"widget_title":"17px"
},
"leading": {
"body":"1.7",
"head":"1.18",
"lead":"1.5",
"json":"1.6"
},
"weight": {
"display":"700",
"head":"700",
"body":"400",
"strong":"700",
"eye":"700"
},
"tracking": {
"eye":"0.14em",
"display":"-0.03em",
"body":"-0.006em",
"badge":"0.08em"
},
"layout": {
"sheet_width":"1000px",
"text_width":"880px",
"gutter":"16px",
"sheet_padding":"56px 64px 64px",
"sheet_padding_mobile":"24px 18px 40px",
"sheet_margin":"28px auto 72px",
"block_gap":"1.15em",
"widget_gap":"28px",
"grid_gap":"14px"
},
"border": {
"sheet":"0px solid",
"sheet_radius":"30px",
"widget":"1px solid",
"widget_radius":"24px",
"card_radius":"24px",
"badge_radius":"999px",
"rule":"1px solid",
"code_radius":"18px",
"accent_bar":"3px"
},
"shadow": {
"sheet":"0 1px 1px rgba(0,0,0,.02),0 6px 26px rgba(0,0,0,.05)",
"widget":"none",
"card_hover":"0 10px 28px -16px rgba(28,27,23,0.35)"
},
"motion": {
"hover":"160ms ease"
}
}
},
"page":"http://google-preview.miscsubjects.com/a/semaglutide-glp1-agonists",
"json":"http://google-preview.miscsubjects.com/a/semaglutide-glp1-agonists.json",
"markdown":"http://google-preview.miscsubjects.com/a/semaglutide-glp1-agonists.md",
"theme":"http://google-preview.miscsubjects.com/article-theme.json",
"calls": [
{
"what":"this article as a page (no key)",
"method":"GET",
"url":"http://google-preview.miscsubjects.com/a/semaglutide-glp1-agonists",
"headers": {}
},
{
"what":"this article as its object (no key)",
"method":"GET",
"url":"http://google-preview.miscsubjects.com/a/semaglutide-glp1-agonists.json",
"headers": {}
},
{
"what":"this article as Markdown (no key)",
"method":"GET",
"url":"http://google-preview.miscsubjects.com/a/semaglutide-glp1-agonists.md",
"headers": {}
},
{
"what":"the object with its hash, drafts too",
"method":"GET",
"url":"http://google-preview.miscsubjects.com/api/jarticles/semaglutide-glp1-agonists",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
}
},
{
"what":"one piece and that piece’s hash",
"method":"GET",
"url":"http://google-preview.miscsubjects.com/api/jarticles/semaglutide-glp1-agonists/at?path=facts",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
}
},
{
"what":"grep: every key or value that matches, with the path to change it",
"method":"GET",
"url":"http://google-preview.miscsubjects.com/api/jarticles/semaglutide-glp1-agonists/grep?q=owner",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
}
},
{
"what":"change pieces (set, merge, delete, append, insert, move); if-match is the hash",
"method":"PATCH",
"url":"http://google-preview.miscsubjects.com/api/jarticles/semaglutide-glp1-agonists",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json",
"if-match":"<hash from the read>"
},
"body": {
"ops": [
{
"op":"set",
"path":"facts.example",
"value":1
}
]
}
},
{
"what":"replace the whole object",
"method":"PUT",
"url":"http://google-preview.miscsubjects.com/api/jarticles/semaglutide-glp1-agonists",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json",
"if-match":"<hash>"
},
"body": {
"slug":"semaglutide-glp1-agonists",
"title":"…"
}
},
{
"what":"fetch every source, hash what came back and check the quote is in it",
"method":"POST",
"url":"http://google-preview.miscsubjects.com/api/jarticles/semaglutide-glp1-agonists/verify",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json"
},
"body": {}
},
{
"what":"an Obsidian-style command",
"method":"POST",
"url":"http://google-preview.miscsubjects.com/api/jarticles/cli",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json"
},
"body": {
"command":"backlinks",
"file":"semaglutide-glp1-agonists"
}
}
]
}